MSH2 and lung cancer: A CRISPR screen in muscle invasive bladder cancer revealed MSH2 as the top candidate gene mediating cisplatin resistance [32], and low MSH2 expression has been linked to a longer survival in lung cancer patients treated with adjuvant cisplatin-based chemotherapy [33].